Back

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in cancer patients with diabetes mellitus

20 May 2025 (10:19 - 10:27)
Organised by: Logo
Congress Presentation Part of: Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies Cardio-Oncology HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Moran Gvili Perelman

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

6 More presentations in this session

Presentation thumbnail
Sacubitril-valsartan reduced H-FABP, hs-cTnT, hs-CRP and monocyte-to-lymphocyte ratio in anthracycline-treated preclinical models through NLRP3-mTOR-AKT pathways
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Heart failure hospitalization and outcomes in cancer patients undergoing immune checkpoint inhibitor treatment: a systematic review and meta-analysis
Doctor N. Sari (Jakarta, ID)
Abstract Slides Video
Presentation thumbnail
The predictive value of baseline troponin measurements in patients treated with immune checkpoint inhibitors
Doctor M. Laufer-Perl (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
GLP1-RA associated with SGLT2i as new therapy of anthracycline-induced cardiotoxicity under hyperglycemia: biochemical and preclinical evidences
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Evaluation of vascular cell adhesion molecule-1 (VCAM-1) level changes in patients with lymphoproliferative diseases during antitumor therapy
Doctor R. Alieva (Tashkent, UZ)
Abstract Slides Video

Access the full session

Session thumbnail
Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies
Video

The Event

Event poster

Heart Failure 2025

20 May 2025 10:19 CET
You may be interested in
thumbnail
Congress Presentation
Effects of SGLT2 inhibitors on the cardiovascular outcomes in patients with cancer: a systematic review and meta-analysis
thumbnail
Congress Presentation
Indications for SGLT2i to prevent cardiovascular toxicity
thumbnail
Congress Session
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources